This week's Biotech scorecard newsletter: (Almost) 100% positive vibes 1. $QURE, of course. The 75% slowing of disease progression reported by Uniqure with its Huntington’s disease gene therapy AMT-130 was the kind of stop-reading-and-gasp moment that crystalizes the profound impact these types of one-time treatments can have for patients dealing with rare diseases. But, bear in mind... The validity of external control arms like the one used by Uniqure is still hotly debated, even as regulators, including the FDA, allow them under certain circumstances. It’s been lost to memory, but recall that the AMT-130 study started with a true, sham-surgery control arm that showed no benefit for the gene therapy. It was only after the company reconfigured the study and started using natural history comparators was a benefit observed. Also: -- Why $STOK 's quiet move higher makes sense. The stock is up almost four-fold from its April low and has doubled year to date. Why? I asked around... -- $ACAD was a "clearing event" for $SLNO. Next up, earnings. What's the whisper number for Vykat sales? Newsletter link below...
Last 12mo stats
4
mentions
1
voices
$ACAD
ACADIA Pharmaceuticals Inc
$ACAD
ACADIA Pharmaceuticals IncPast 12mo:4mentions1voices
All voices4 mentions since Sep 2025calls only
Loading price chart…
Frequently asked
Who mentions $ACAD most on Surfaced?
@adamfeuerstein (Adam Feuerstein ✡️) mentions $ACAD most — 4 mentions in the past 12 months.
When was $ACAD first mentioned on Surfaced?
The earliest tracked mention of $ACAD in the Surfaced archive was on Sep 24, 2025.
How many voices track $ACAD?
1 FinTwit voice has mentioned $ACAD 4 times in the past 12 months.
What kind of voices mention $ACAD most?
$ACAD is mentioned most by Biotech voices on Surfaced.